What is it about?
PD-1 is a limphocytes receptor that blocks immune response through the bind with its main ligand,PD-L1, expressed on tumour cells. Using antibodies that target PD-1 or PD-L1 may cause an effective tumour immune response.
Featured Image
Why is it important?
Our work summarise the results regarding the efficacy of these agents in the treatment of metastatic melanoma and it also discuss some of the most important pending issues about their use in melanoma
Perspectives
Our work may give a brief summary about the most recent treatments in metastatic melanoma,also outlining their actual limits
Ester Simeone
National Cancer Research Institute
Read the Original
This page is a summary of: Anti-PD-1 and PD-L1 antibodies in metastatic melanoma, Melanoma Management, November 2017, Future Medicine,
DOI: 10.2217/mmt-2017-0018.
You can read the full text:
Contributors
The following have contributed to this page
